

Loose translation for information purposes only. In case of any discrepancy, the Spanish version prevails

PROPOSED RESOLUTIONS SUBMITTED BY THE BOARD OF DIRECTORS TO THE GENERAL SHAREHOLDERS MEETING OF IBI LION SOCIMI, S.A., TO BE HELD ON 22 JUNE 2026 AND 23 JUNE 2026, ON FIRST AND SECOND CALL, RESPECTIVELY

ITEM ONE ON THE AGENDA

Review and approval, if applicable, of the individual annual accounts of IBI Lion SOCIMI, S.A. and the consolidated annual accounts with its subsidiaries, for the financial year ended 31 December 2025

Approve the individual annual accounts of IBI Lion SOCIMI, S.A. (which consist of the balance sheet, the profit and loss account, the statement of changes in equity, the cash flow statement and the notes to the financial statements) and the consolidated accounts including its subsidiaries (which consist of the statement of financial position, the income statement, the statement of comprehensive income, the cash flow statement and the notes to the financial statements), corresponding to the fiscal year ended on 31 December 2025, as prepared by the board of directors at its meeting held on 31 March 2026.

ITEM TWO ON THE AGENDA

Review and approval, if applicable, of the individual management report of IBI Lion SOCIMI, S.A. and the consolidated management report with its subsidiaries, for the financial year ended 31 December 2025

Approve the individual management report of IBI Lion SOCIMI, S.A., ante the consolidated report including its subsidiaries, corresponding to the fiscal year ended on 31 December 2025, as prepared by the board of directors at its meeting held on 31 March 2026.

ITEM THREE ON THE AGENDA

Review and approval, if applicable, of the management and performance of the board of directors of IBI Lion SOCIMI, S.A. during the financial year ended 31 December 2025

Approve the management and activity carried out by the board of directors of IBI Lion SOCIMI, S.A., in the fiscal year ended on 31 December 2025.

ITEM FOUR ON THE AGENDA

Review and approval, if applicable, of the proposed allocation of the individual results for the financial year ended 31 December 2025

Approve the proposed application of individual income of IBI Lion SOCIMI, S.A., as formulated by the board of directors at its meeting held on 31 March 2026 and specified below:

Loss:	Euros
Loss for the year ended on 31 December 2025	(2,862,398)
Application:	
To negative results from previous years	(2,862,398)

ITEM FIVE ON THE AGENDA

Re-appointment, where applicable, of Mr. David Lubetzky as director for the statutory term of six years

To re-appoint Mr. David Lubetzky, of legal age, of Israeli nationality, holder of NIE number [...] currently in force, and with address for these purposes at Calle Velázquez 17, 5º left, 28801, Madrid, Spain, as director of IBI Lion SOCIMI, S.A. for the statutory term of six years, effective as from the date of this General Meeting of Shareholders.

Mr. David Lubetzky shall accept his re-appointment by any means valid in law.

ITEM SIX ON THE AGENDA

Re-appointment, where applicable, of Mr. Nadav Berkovitch as director for the statutory term of six years

To re-appoint Mr. Nadav Berkovitch, of legal age, of Israeli nationality, holder of NIE number [...] currently in force, and with address for these purposes at Calle Velázquez 17, 5º left, 28801, Madrid, Spain, as director of IBI Lion SOCIMI, S.A. for the statutory term of six years, effective as from the date of this General Meeting of Shareholders.

Mr. Nadav Berkovitch shall accept his re-appointment by any means valid in law.

ITEM SEVEN ON THE AGENDA

Re-appointment, where applicable, of Mr. Rafael Goldfeld as director for the statutory term of six years

To re-appoint Mr. Rafael Goldfeld, of legal age, of Israeli nationality, holder of NIE number [...] currently in force, and with address for these purposes at Calle Velázquez 17, 5º left, 28801, Madrid, Spain, as director of IBI Lion SOCIMI, S.A. for the statutory term of six years, effective as from the date of this General Meeting of Shareholders.

Mr. Rafael Goldfeld shall accept his re-appointment by any means valid in law.

ITEM EIGHT ON THE AGENDA

Re-appointment, where applicable, of Mr. Ohad Kleiner as director for the statutory term of six years

To re-appoint Mr. Ohad Kleiner, of legal age, of Israeli nationality, holder of NIE number [...] currently in force, and with address for these purposes at Calle Velázquez 17, 5º left, 28801, Madrid, Spain, as director of IBI Lion SOCIMI, S.A. for the statutory term of six years, effective as from the date of this General Meeting of Shareholders.

Mr. Ohad Kleiner shall accept his re-appointment by any means valid in law.

ITEM NINE ON THE AGENDA

Review and approval, if applicable, of a share capital reduction for the purpose of returning contributions to the shareholders, by reducing the nominal value of the shares by 0.031 euros, in the total amount, considering the number of shares currently outstanding, of 2,419,398.63 euros (with express delegation to adjust such total amount depending on the number of shares outstanding at the time of its execution), and the corresponding amendment of article 6 of the bylaws

To reduce the share capital of IBI Lion SOCIMI, S.A. (the “**Company**”) by reducing by EUR 0.031 the nominal value of the shares, with the aim of refunding shareholder contributions, all in accordance with the provisions of article 317 of the consolidated text of the Spanish Companies Law approved by Royal Legislative Decree 1/2010 of 2 July (the “LSC”). As a consequence of this reduction, the nominal value of the shares will change from EUR 0.805 to EUR 0.774 and the difference of EUR 0.031 per share will be paid to the shareholders of the Company.

Consequently, considering that at the time of calling this general meeting there are 78,045,117 outstanding shares of the Company, the amount of the capital reduction object of this resolution amounts to EUR 2,419,398.63. If, prior to the execution of the capital reduction that is the object of this resolution, the number of outstanding shares of the Company has increased, the aggregate total amount of the capital reduction shall also increase by the corresponding amount. It is resolved to grant powers in favour of the Board of Directors, with express powers of substitution in each of its members, to adapt that total amount in light of the number of shares outstanding upon execution of the capital reduction.

The execution of this capital reduction resolution must be carried out following the end of the term for the exercise of the creditors' right of opposition established in article 334 of the LSC, as set forth in article 336 of such law. Notwithstanding the above, the capital reduction provided for in this resolution must be executed within a maximum period of one year from the date of this resolution.

In accordance with article 334 of the LSC, Company's creditors whose credits arose prior to the date of the last announcement of the capital reduction resolution, have not matured at that time and until such credits are secured, will have the right to oppose the capital reduction

Once the capital reduction provided for in this resolution has been executed, article 6 of the Company's articles of association, related to the share capital, shall be amended as to reflect the resulting share capital and number of shares outstanding. Consequently, assuming that no capital increase is carried out prior to the execution of this capital reduction, article 6 of the articles of association will be drafted as follows: “The share capital amounts to sixty million four hundred six thousand nine hundred twenty euros and fifty-five cents (EUR 60,406,920.55), divided into seventy-eight million forty-five thousand one hundred seventeen (78,045,117) registered shares, each with a nominal value of zero euros and eighty three five cents of an euro (EUR 0.805), fully subscribed and paid up, of a single series and class. All shares are fully subscribed and paid up and grant their holders the same rights”. In case that, before the execution of the capital reduction the number of outstanding shares has increased, the language of article 6 of the Company's articles of association will be adapted consequently. It is resolved to grant powers in favour of the Board of Directors, with express powers of substitution in each of its members, to draft the referred article of the Company's articles of association.

Payment of the amount of 0.031 euros per share will be paid to shareholders in accordance with applicable legislation on depositories entities and through the mechanisms made available to participating entities by Sociedad de Gestión de los Sistemas de Registro, Compensación y Liquidación de Valores, S.A.U. (Iberclear).

Furthermore, it is resolved to jointly and severally delegate to the board of directors, its chairman, the secretary member of the board of directors, the vice-secretary non-member of the board of directors, and the rest of the members of the board so that any of them, jointly and severally and indistinctly, as broadly as required by the law, may proceed to the execution of this resolution and may determine the points that have not been expressly set out in this resolution or which are a consequence of it. In particular, including but not limited to, it is resolved to jointly and severally delegate to the aforementioned persons, as broadly as required by the law, the following powers:

- (i) in the event that, prior to the execution of the capital reduction object of this resolution, the number of outstanding shares of the Company had increased as a result of the implementation of any capital increase, adjust the aggregate total amount of the capital reduction covered by this resolution, taking into account the new number of shares outstanding at the time of its implementation;
- (ii) to extend and develop this resolution, establishing the terms and conditions of the reduction in all matters not provided for herein and in particular, the exact date on which the return of the shareholders' contributions will become effective;
- (iii) to carry out any actions needed to meet the requirements set by the LSC, Law 6/2023, of March 17, on the Securities Market and Investment Services, the Royal Decree 878/2015 of 2 October, on clearing, settlement and registration of tradable securities in the form of book entries, on the legal regime of central securities depositories and central counterparty entities, and on transparency requirements in relation to information about issuers whose securities are admitted to trading in an official secondary market, and other applicable regulations;
- (iv) to carry out any actions and procedures that may be necessary to obtain the consent and authorizations required for the full effectiveness of this resolution;
- (v) to carry out, on behalf to the Company, any act, statement or procedure that may be required by the Spanish National Securities Market Commission (Comisión Nacional del Mercado de Valores, "CNMV"), BME Growth segment of BME MTF Equity, the Sociedad de Gestión de los Sistemas de Registro, Compensación y Liquidación de Valores, S.A.U. (Iberclear), Sociedades Rectoras de las Bolsas, Servicio de Liquidación y Compensación de Valores and any other body, entity or register, public or private, national or foreign, in relation to the capital reduction provided for in this resolution;
- (vi) to amend the article of the articles of association related to share capital, as to reflect the new share capital and nominal value of the shares, in particular, amending the wording of article 6 of the articles of association referred to in the text of this resolution in the event that prior to the implementation of the capital reduction covered by this resolution a capital increase had been implemented;
- (vii) to draft and publish all the notices that are required or convenient in relation to this share capital reduction,
- (viii) to declare, in due course, the expiry of the period for creditors to lodge objections, as well as, where appropriate, to attend to the exercise of the right of objection of those creditors who may exercise it in accordance with the terms provided for in the Law;
- (ix) to grant, on behalf of the Company, as many public or private documents may be necessary or convenient for the capital reduction;
- (x) to declare the capital reduction closed and implemented and to establish any other circumstances necessary to implement it;
- (xi) to make, if appropriate, the corresponding tax withholdings on the amount of the value of the contributions refunded to the shareholders in respect of the capital reduction, to be paid on behalf of the shareholders to the competent Spanish tax authorities, in particular, and by way of illustration only, those derived from the Tax on Capital Transfers and Documented Legal Acts in the form of Corporate Transactions;

- (xii) to rectify, clarify, interpret, specify or supplement this resolution, or any resolutions adopted, in any deeds or documents executed in connection therewith, and, in particular, to remedy any defects, omissions or errors, whether substantive or formal, that may prevent the registration of this resolution and its consequences with the Mercantile Registry, the official registers of the CNMV, BME Growth of BME MTF Equity or any other registries;
- (xiii) to resolve not to implement this resolution if, in its judgment, circumstances arise that justify such decision in light of the corporate interest; and;
- (xiv) in general, to carry out any actions necessary or appropriate for the proper execution of this resolution and the effective reduction of share capital.

ITEM TEN ON THE AGENDA

Review and, where appropriate, approval of the following share capital increases:

Each of the proposals included under items (A) to (C) will be put to vote separately.

- (A) **Share capital increase for a maximum nominal amount of EUR 48,300,000 through the issuance and admission to circulation of up to 60,000,000 new ordinary shares with a nominal value of EUR 0.805 each (or such nominal value as may result if the Company resolves to amend it), to be fully subscribed and paid up in cash contributions, with the share premium to be determined by the board of directors, with recognition of pre-emptive subscription rights and with provision for incomplete subscription. Delegation to the board of directors, with powers of substitution, of the necessary powers to implement the capital increase and to determine the terms and conditions thereof in all matters not provided for in the resolution, pursuant to article 297.1.a) of the Spanish Companies Act (Ley de Sociedades de Capital), as well as to amend article 6 of the bylaws accordingly.**

1. Capital share increase

It is resolved to increase the share capital, by means of cash contributions, in order to increase the equity of IBI Lion SOCIMI, S.A. (the "**Company**"), by a maximum nominal amount of EUR 48,300,000, by issuing and putting into circulation a maximum of 60,000,000 new ordinary shares of EUR 0.805 of nominal value each (or EUR 0.774 of nominal value each if the increase is carried out once the capital reduction submitted to the general shareholders meeting under item Five of the agenda is effective), of the same class and series as those currently in circulation, represented by book entries.

It is also resolved to expressly delegate to the board of directors the power not to execute this resolution if, in its opinion, in view of the corporate interest, market conditions in general or the financial structure resulting from the capital increase transaction or other circumstances that may affect the Company make the execution of this resolution inadvisable or impossible.

The Company's board of directors, or the person to whom it may decide to substitute or delegate this power, shall be responsible for determining, based on market conditions at the time of execution of this resolution, taking into account the number of treasury shares and the type or issue price, the exchange ratio for the exercise of pre-emptive subscription rights.

2. Issue price

The board of directors, or the person to whom it may decide to substitute or delegate this power, shall determine, based on market conditions at the time of execution of this reduction: (i) the total nominal amount of, and the number of ordinary shares to be issued in the increase; and (ii) the unit issue price of the new shares and, in particular, the amount of the share premium, if any, to be determined for each new share:

In its decision, the board of directors shall take into account the following parameters:

- the issue price may not be less than the nominal value of the new shares, in accordance with article 59 of the consolidated text of the Spanish Companies Law as approved by Royal Legislative Decree 1/2010 of 2 July (the "**LSC**").
- (i) the total nominal amount of the capital increase shall be a maximum of EUR 48,300,000; and (ii) the maximum number of ordinary shares to be issued shall be a maximum of 60,000,000 shares

3. Maximum execution period

The board of directors, with express power of substitution in any of its members, shall be responsible for determining the date on which the resolution is to be executed within a maximum period of one year from the date of this resolution, after which time this resolutions shall be of no force and effect.

4. Addresses

The capital increase is addressed to all shareholders of the Company who acquire shares, in sufficient number, up to 23:59 hours on the same trading business day on which the corresponding announcement of the capital increase is published in the Official Gazette of the Commercial Registry (*Boletín Oficial del Registro Mercanti* or “**BORME**”), and whose transactions have been settled in the accounting records of Sociedad de Gestión de los Sistemas de Registro, Compensación y Liquidación de Valores, S.A.U. (“**Iberclear**”) and its participating entities up to the second trading business day following the publication of the announcement in the BORME, without prejudice to the possibility that other investors may subscribe shares through the acquisition of pre-emptive subscription rights, whether or not they are shareholders, as well as the possibility of offering those shares that have not been subscribed by holders of pre-emptive subscription rights to shareholders of the Company interested in subscribing an additional number of shares of the Company or to third party investors, both national and international.

In any event, the Company shall comply with any requirements necessary to be able to apply the exemption from the obligation to publish a prospectus provided for in article 1.4 of Regulation 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market and repealing Directive 2003/71/EC.

5. Subscription of the new shares

5.1. Pre-emptive subscription period

Pursuant to the provisions of article 304 of the LSC, shareholders shall be entitled to subscribe a number of shares proportional to the nominal value of the shares they hold.

Pre-emptive subscription rights shall be allocated to the Company's shareholders who have acquired shares, in sufficient number, up to 23:59 hours on the same trading business day on which the corresponding announcement of the capital increase is published in the BORME, and whose transactions have been settled in Iberclear and its participating entities up to the second trading business day following the aforementioned publication of the announcement in the BORME.

It is resolved to delegate to the board of directors, with express powers of substitution, the setting of the exchange ratio for the exercise of pre-emptive subscription rights, for which purpose it shall take into consideration the number of shares in circulation at the time of allocation of the pre-emptive subscription rights, as well as the legal regime applicable to treasury shares and the restrictions applicable to preemptive subscription rights.

Pursuant to article 503 of the LSC, in connection with the thirteenth additional provision of the same legal text, the pre-emptive subscription period shall last at least fourteen days from the publication of the announcement of the capital increase resolution in the BORME (the “**Pre-emptive Subscription Period**”).

The pre-emptive subscription rights will be transferable under the same conditions as the shares from which they derive and will be tradable on the BME Growth segment of BME MTF Equity (“**BME Growth**”), the multilateral trading system on which the Company's shares are listed for trading, pursuant to the provisions of article 306.2 of the LSC.

Pre-emptive subscription rights not exercised by the Company's shareholders to whom they have been attributed, or by those investors or shareholders who have acquired them on the market, will be automatically extinguished at the end of the Pre-emptive Subscription Period.

5.2. Additional subscription periods

The issue will be subscribed in one or more successive subscription periods and on such terms and conditions as may be determined by the board of directors. For this purpose, it is resolved to expressly delegate to the board of directors the power to establish successive subscription periods, as well as to set the conditions and terms thereof, including the duration and conditions of each of the periods.

In this respect, all shares not subscribed during the Pre-emptive Subscription Period may be distributed among shareholders of the Company interested in subscribing an additional number of shares of the Company or third party investors, both national and international, and a book-building period may be used.

In this respect, the board of directors is empowered to enter into any underwriting or placement agreement for the capital increase deemed appropriate for its successful completion, on the terms set out in section 12 of this resolution. To this end, the board of directors is empowered, with express powers of substitution, to manage this process and to participate in the appointment, if necessary, of one or more agent entities.

6. Payment of the new shares

The payment of the new shares, including their nominal value and the corresponding issue premium, to be issued under this resolution shall be made entirely by means of cash contributions at the time of subscription.

For the purposes of provisions of article 299 of the LSC, it is hereby stated that the previously issued shares of the Company are fully paid.

7. Representation of the new shares

The newly issued shares shall be represented by book entries, which shall be kept by Iberclear and its participating entities, under the terms established in the regulations in force from time to time.

8. Rights of the new shares

The new shares are ordinary shares, belong to the same class as the other ordinary shares of the Company currently in circulation and confer the same rights and obligations as the latter as from the date on which the capital increase is declared subscribed and paid up.

9. Incomplete subscription

The possibility of incomplete subscription of the capital increase is expressly provided. Accordingly, if the capital increase is not fully subscribed within the period fixed for subscription, the share capital of the Company shall be increased by the amount actually subscribed.

10. Incorporation of the new shares into the BME Growth segment of BME MTF Equity

It is resolved to request the listing of all the ordinary shares issued in execution of this resolution on BME Growth and to carry out the necessary or appropriate procedures and actions and submit the necessary documents to the competent bodies for the listing of the new shares issued as a result of the agreed capital increase, expressly stating the Company's submission to the rules that exist or may be issued in relation to BME Growth and, in particular, on trading, continued listing and delisting.

11. Amendment of article 6 of the articles of association

It is resolved to expressly authorize the board of directors, with express powers of substitution, so that, once the capital increase has been carried out, it may adapt the wording of article 6 of the articles of association relating to share capital to the final result of the capital increase.

12. Delegation of powers

It is resolved to delegate to the board of directors, pursuant to the provisions of article 297.1.a) of the LSC, with express powers of substitution, the power to set the date on which the resolution adopted to increase the share capital must be carried into effect, within the period indicated in section 3 above, and, to the extent necessary, to amend article 6 of the articles of association as appropriate with regard to the new figure for the share capital and the number of shares into which it is divided.

It is also resolved to delegate to the board of directors, also in accordance with the provisions of article 297.1.a) of the LSC and also with express powers of substitution, the power to set the terms and conditions of the capital increase in all matters not provided for in the preceding paragraphs. In particular, and without the following list being exhaustive or implying any limitation or restriction whatsoever, the powers are delegated to:

- (i) Develop, supplement and interpret this resolution, setting the terms and conditions of the capital increase in all matters not determined by the general meeting. In particular, without being exhaustive, to determine the time and manner of its implementation, the issue premium for the new shares and, therefore, to set the issue price of the new shares, the amount at which the capital increase is to be implemented, the setting of one or more additional and successive subscription periods to the Pre-emptive Subscription Period, as well as the recipients of such successive subscription periods, the possibility of offering the subscription of the increase to non-shareholders (after the end of the Pre-emptive Subscription Period) and the corresponding placement procedure or system, the date or period of subscription and payment or issue, the entities involved in the placement or in the underwriting of the issue, the method, if any, of offering the increase to non-shareholders (after the end of the Pre-emptive Subscription Period) and the corresponding placement procedure or system, the date or period of subscription and payment or issue, the entities involved in the placement or in the underwriting, where applicable, the method of allotment in the event that the securities requested by investors exceed the total securities offered, in general, the set of rules governing the issue, the exchange ratio for the exercise of pre-emptive subscription rights, the power to propose to one or more shareholders the waiver of such number of pre-emptive subscription rights held by them as may be necessary to ensure that the number of shares to be issued maintains exactly the proportion resulting from the application of the agreed exchange ratio and, in general, any other circumstances for the implementation of the increase and the issue of shares in consideration for the cash contributions;
- (ii) Declare the capital increase executed and closed once the new shares have been subscribed and paid up, determining, in the event of incomplete subscription of the increase, the final amount of the capital increase and the number of shares subscribed;
- (iii) Amend the wording of article 6 of the articles of association as a result of the outcome of the capital increase;
- (iv) Appear before the notary of their choice and convert this resolution into a public deed, as well as take such actions as may be necessary or advisable to carry out the execution, formalisation and registration of the capital increase and the corresponding amendment to the articles of association, before any public or private, Spanish or foreign entities and bodies, particularly before the Commercial Registry, including those of formalizing the resolution in a public deed, and those of clarifying, supplementing or remedying any defects or omissions that may prevent or hinder the full effectiveness of the resolution and its registration in the Commercial Registry;

- (v) Draw up, sign and file the corresponding prospectus, reduced or complete document of the capital increase and any other documentation necessary or appropriate for the authorization, verification and execution of the capital increase, as well as for the admission or listing of the new shares, with the National Securities Market Commission, BME Growth, the Governing Bodies of the Stock Exchanges, Sociedad de Bolsas, Iberclear and any other public or private, Spanish or foreign
- (vi) body or entity or registry or any other competent authority, assuming responsibility for the content of such documentation, as well as drafting, signing and submitting such additional documentation as may be required and such supplements as may be necessary or advisable, requesting verification and registration thereof by any competent authority, as the case may be, as well as drafting, signing and submitting to any other competent Spanish or foreign authorities such additional or supplementary information or documentation as may be required, assuming responsibility for the content thereof and requesting verification and registration thereof, as the case may be;
- (vii) Draft, sign and execute such public or private documents as may be necessary in connection with the international aspect, if any, of the capital increase, including the International Offering Memorandum in its preliminary and definitive versions, as well as take any actions, make any statements or dealings that may be required before the competent authorities of the United States or other countries in which shares are offered by virtue of the capital increase and, in particular, before the SEC (Securities Exchange Commission), including, if appropriate, the application for such exemptions as may be appropriate;
- (viii) Carry out any action, declaration or task before any other public or private, Spanish or foreign, body, entity or registry in order to obtain authorization, verification and subsequent execution of the capital increase;
- (ix) Negotiate, sign and execute such public or private documents as may be necessary in connection with the capital increase in accordance with practice in this type of transaction, including, in particular, one or more placement or underwriting agreements for the capital increase, if applicable, which may include, in turn and among other provisions, any representations and guarantees customary in this type of agreement, agency agreements, deposit agreements in relation to the funds raised in the capital increase or pre-agreements relating to the aforementioned placement or underwriting agreements, as well as such other agreements as may be appropriate for the best possible purpose of the capital increase, including but not limited to securities lending and green shoe option agreements in order to meet possible excess demand for the offer, agreeing the fees and other terms and conditions deemed appropriate, including commitments not to issue or transfer (lock-up) shares in the Company or similar securities by the Company and the current shareholders of the Company and indemnification of the underwriters, if any;
- (x) Appoint the underwriters or underwriters of the issue, and an agent entity, and negotiate the terms of their intervention;
- (xi) Draw up and publish such notices as may be necessary or advisable;
- (xii) Draw up, sign, execute and, where appropriate, certify any type of document relating to the issue and to the admission or incorporation of the new shares;
- (xiii) Carry out all the necessary procedures to ensure that the new shares covered by the capital increase are recorded in Iberclear's accounting records and included in BME Growth;
- (xiv) Carry out all actions that must be carried out by the Company in accordance with the terms and conditions of the capital increase;
- (xv) Agree not to execute this resolution if, in its opinion, there are reasons that justify it; and;
- (xvi) In general, to take such actions as may be necessary or advisable for the successful completion of the capital increase.

ITEM TEN ON THE AGENDA

Review and, where appropriate, approval of the following share capital increases:

Each of the proposals included under items (A) to (C) will be put to vote separately.

- (B) Share capital increase for a maximum nominal amount of EUR 24,150,000 through the issuance and admission to circulation of up to 30,000,000 new ordinary shares with a nominal value of EUR 0.805 each (or such nominal value as may result if the Company resolves to amend it), to be fully subscribed and paid up in cash contributions, with the share premium to be determined by the board of directors, with recognition of pre-emptive subscription rights and with provision for incomplete subscription. Delegation to the board of directors, with powers of substitution, of the necessary powers to implement the capital increase and to determine the terms and conditions thereof in all matters not provided for in the resolution, pursuant to article 297.1.a) of the Spanish Companies Act (Ley de Sociedades de Capital), as well as to amend article 6 of the bylaws accordingly.**

1. Capital share increase

It is resolved to increase the share capital, by means of cash contributions, in order to increase the equity of IBI Lion SOCIMI, S.A. (the "**Company**"), by a maximum nominal amount of EUR 24,150,000, by issuing and putting into circulation a maximum of 30,000,000 new ordinary shares of EUR 0.805 of nominal value each (or EUR 0.774 of nominal value each if the increase is carried out once the capital reduction submitted to the general shareholders meeting under item Five of the agenda is effective), of the same class and series as those currently in circulation, represented by book entries.

It is also resolved to expressly delegate to the board of directors the power not to execute this resolution if, in its opinion, in view of the corporate interest, market conditions in general or the financial structure resulting from the capital increase transaction or other circumstances that may affect the Company make the execution of this resolution inadvisable or impossible.

The Company's board of directors, or the person to whom it may decide to substitute or delegate this power, shall be responsible for determining, based on market conditions at the time of execution of this resolution, taking into account the number of treasury shares and the type or issue price, the exchange ratio for the exercise of pre-emptive subscription rights.

2. Issue price

The board of directors, or the person to whom it may decide to substitute or delegate this power, shall determine, based on market conditions at the time of execution of this reduction: (i) the total nominal amount of, and the number of ordinary shares to be issued in the increase; and (ii) the unit issue price of the new shares and, in particular, the amount of the share premium, if any, to be determined for each new share:

In its decision, the board of directors shall take into account the following parameters:

- the issue price may not be less than the nominal value of the new shares, in accordance with article 59 of the consolidated text of the Spanish Companies Law as approved by Royal Legislative Decree 1/2010 of 2 July (the "**LSC**").
- (i) the total nominal amount of the capital increase shall be a maximum of EUR 24,150,000; and (ii) the maximum number of ordinary shares to be issued shall be a maximum of 30,000,000 shares

3. Maximum execution period

The board of directors, with express power of substitution in any of its members, shall be responsible for determining the date on which the resolution is to be executed within a maximum period of one year from the date of this resolution, after which time this resolutions shall be of no force and effect.

4. Addresses

The capital increase is addressed to all shareholders of the Company who acquire shares, in sufficient number, up to 23:59 hours on the same trading business day on which the corresponding announcement of the capital increase is published in the Official Gazette of the Commercial Registry (*Boletín Oficial del Registro Mercanti* or “**BORME**”), and whose transactions have been settled in the accounting records of Sociedad de Gestión de los Sistemas de Registro, Compensación y Liquidación de Valores, S.A.U. (“**Iberclear**”) and its participating entities up to the second trading business day following the publication of the announcement in the BORME, without prejudice to the possibility that other investors may subscribe shares through the acquisition of pre-emptive subscription rights, whether or not they are shareholders, as well as the possibility of offering those shares that have not been subscribed by holders of pre-emptive subscription rights to shareholders of the Company interested in subscribing an additional number of shares of the Company or to third party investors, both national and international.

In any event, the Company shall comply with any requirements necessary to be able to apply the exemption from the obligation to publish a prospectus provided for in article 1.4 of Regulation 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market and repealing Directive 2003/71/EC.

5. Subscription of the new shares

5.1. Pre-emptive subscription period

Pursuant to the provisions of article 304 of the LSC, shareholders shall be entitled to subscribe a number of shares proportional to the nominal value of the shares they hold.

Pre-emptive subscription rights shall be allocated to the Company's shareholders who have acquired shares, in sufficient number, up to 23:59 hours on the same trading business day on which the corresponding announcement of the capital increase is published in the BORME, and whose transactions have been settled in Iberclear and its participating entities up to the second trading business day following the aforementioned publication of the announcement in the BORME.

It is resolved to delegate to the board of directors, with express powers of substitution, the setting of the exchange ratio for the exercise of pre-emptive subscription rights, for which purpose it shall take into consideration the number of shares in circulation at the time of allocation of the pre-emptive subscription rights, as well as the legal regime applicable to treasury shares and the restrictions applicable to preemptive subscription rights.

Pursuant to article 503 of the LSC, in connection with the thirteenth additional provision of the same legal text, the pre-emptive subscription period shall last at least fourteen days from the publication of the announcement of the capital increase resolution in the BORME (the “**Pre-emptive Subscription Period**”).

The pre-emptive subscription rights will be transferable under the same conditions as the shares from which they derive and will be tradable on the BME Growth segment of BME MTF Equity (“**BME Growth**”), the multilateral trading system on which the Company's shares are listed for trading, pursuant to the provisions of article 306.2 of the LSC.

Pre-emptive subscription rights not exercised by the Company's shareholders to whom they have been attributed, or by those investors or shareholders who have acquired them on the market, will be automatically extinguished at the end of the Pre-emptive Subscription Period.

5.2. Additional subscription periods

The issue will be subscribed in one or more successive subscription periods and on such terms and conditions as may be determined by the board of directors. For this purpose, it is resolved to expressly delegate to the board of directors the power to establish successive subscription periods, as well as to set the conditions and terms thereof, including the duration and conditions of each of the periods.

In this respect, all shares not subscribed during the Pre-emptive Subscription Period may be distributed among shareholders of the Company interested in subscribing an additional number of shares of the Company or third party investors, both national and international, and a book-building period may be used.

In this respect, the board of directors is empowered to enter into any underwriting or placement agreement for the capital increase deemed appropriate for its successful completion, on the terms set out in section 12 of this resolution. To this end, the board of directors is empowered, with express powers of substitution, to manage this process and to participate in the appointment, if necessary, of one or more agent entities.

6. Payment of the new shares

The payment of the new shares, including their nominal value and the corresponding issue premium, to be issued under this resolution shall be made entirely by means of cash contributions at the time of subscription.

For the purposes of provisions of article 299 of the LSC, it is hereby stated that the previously issued shares of the Company are fully paid.

7. Representation of the new shares

The newly issued shares shall be represented by book entries, which shall be kept by Iberclear and its participating entities, under the terms established in the regulations in force from time to time.

8. Rights of the new shares

The new shares are ordinary shares, belong to the same class as the other ordinary shares of the Company currently in circulation and confer the same rights and obligations as the latter as from the date on which the capital increase is declared subscribed and paid up.

9. Incomplete subscription

The possibility of incomplete subscription of the capital increase is expressly provided. Accordingly, if the capital increase is not fully subscribed within the period fixed for subscription, the share capital of the Company shall be increased by the amount actually subscribed.

10. Incorporation of the new shares into the BME Growth segment of BME MTF Equity

It is resolved to request the listing of all the ordinary shares issued in execution of this resolution on BME Growth and to carry out the necessary or appropriate procedures and actions and submit the necessary documents to the competent bodies for the listing of the new shares issued as a result of the agreed capital increase, expressly stating the Company's submission to the rules that exist or may be issued in relation to BME Growth and, in particular, on trading, continued listing and delisting.

11. Amendment of article 6 of the articles of association

It is resolved to expressly authorize the board of directors, with express powers of substitution, so that, once the capital increase has been carried out, it may adapt the wording of article 6 of the articles of association relating to share capital to the final result of the capital increase.

12. Delegation of powers

It is resolved to delegate to the board of directors, pursuant to the provisions of article 297.1.a) of the LSC, with express powers of substitution, the power to set the date on which the resolution adopted to increase the share capital must be carried into effect, within the period indicated in section 3 above, and, to the extent necessary, to amend article 6 of the articles of association as appropriate with regard to the new figure for the share capital and the number of shares into which it is divided.

It is also resolved to delegate to the board of directors, also in accordance with the provisions of article 297.1.a) of the LSC and also with express powers of substitution, the power to set the terms and conditions of the capital increase in all matters not provided for in the preceding paragraphs. In particular, and without the following list being exhaustive or implying any limitation or restriction whatsoever, the powers are delegated to:

- (i) Develop, supplement and interpret this resolution, setting the terms and conditions of the capital increase in all matters not determined by the general meeting. In particular, without being exhaustive, to determine the time and manner of its implementation, the issue premium for the new shares and, therefore, to set the issue price of the new shares, the amount at which the capital increase is to be implemented, the setting of one or more additional and successive subscription periods to the Pre-emptive Subscription Period, as well as the recipients of such successive subscription periods, the possibility of offering the subscription of the increase to non-shareholders (after the end of the Pre-emptive Subscription Period) and the corresponding placement procedure or system, the date or period of subscription and payment or issue, the entities involved in the placement or in the underwriting of the issue, the method, if any, of offering the increase to non-shareholders (after the end of the Pre-emptive Subscription Period) and the corresponding placement procedure or system, the date or period of subscription and payment or issue, the entities involved in the placement or in the underwriting, where applicable, the method of allotment in the event that the securities requested by investors exceed the total securities offered, in general, the set of rules governing the issue, the exchange ratio for the exercise of pre-emptive subscription rights, the power to propose to one or more shareholders the waiver of such number of pre-emptive subscription rights held by them as may be necessary to ensure that the number of shares to be issued maintains exactly the proportion resulting from the application of the agreed exchange ratio and, in general, any other circumstances for the implementation of the increase and the issue of shares in consideration for the cash contributions;
- (ii) Declare the capital increase executed and closed once the new shares have been subscribed and paid up, determining, in the event of incomplete subscription of the increase, the final amount of the capital increase and the number of shares subscribed;
- (iii) Amend the wording of article 6 of the articles of association as a result of the outcome of the capital increase;
- (iv) Appear before the notary of their choice and convert this resolution into a public deed, as well as take such actions as may be necessary or advisable to carry out the execution, formalisation and registration of the capital increase and the corresponding amendment to the articles of association, before any public or private, Spanish or foreign entities and bodies, particularly before the Commercial Registry, including those of formalizing the resolution in a public deed, and those of clarifying, supplementing or remedying any defects or omissions that may prevent or hinder the full effectiveness of the resolution and its registration in the Commercial Registry;

- (v) Draw up, sign and file the corresponding prospectus, reduced or complete document of the capital increase and any other documentation necessary or appropriate for the authorization, verification and execution of the capital increase, as well as for the admission or listing of the new shares, with the National Securities Market Commission, BME Growth, the Governing Bodies of the Stock Exchanges, Sociedad de Bolsas, Iberclear and any other public or private, Spanish or foreign
- (vi) body or entity or registry or any other competent authority, assuming responsibility for the content of such documentation, as well as drafting, signing and submitting such additional documentation as may be required and such supplements as may be necessary or advisable, requesting verification and registration thereof by any competent authority, as the case may be, as well as drafting, signing and submitting to any other competent Spanish or foreign authorities such additional or supplementary information or documentation as may be required, assuming responsibility for the content thereof and requesting verification and registration thereof, as the case may be;
- (vii) Draft, sign and execute such public or private documents as may be necessary in connection with the international aspect, if any, of the capital increase, including the International Offering Memorandum in its preliminary and definitive versions, as well as take any actions, make any statements or dealings that may be required before the competent authorities of the United States or other countries in which shares are offered by virtue of the capital increase and, in particular, before the SEC (Securities Exchange Commission), including, if appropriate, the application for such exemptions as may be appropriate;
- (viii) Carry out any action, declaration or task before any other public or private, Spanish or foreign, body, entity or registry in order to obtain authorization, verification and subsequent execution of the capital increase;
- (ix) Negotiate, sign and execute such public or private documents as may be necessary in connection with the capital increase in accordance with practice in this type of transaction, including, in particular, one or more placement or underwriting agreements for the capital increase, if applicable, which may include, in turn and among other provisions, any representations and guarantees customary in this type of agreement, agency agreements, deposit agreements in relation to the funds raised in the capital increase or pre-agreements relating to the aforementioned placement or underwriting agreements, as well as such other agreements as may be appropriate for the best possible purpose of the capital increase, including but not limited to securities lending and green shoe option agreements in order to meet possible excess demand for the offer, agreeing the fees and other terms and conditions deemed appropriate, including commitments not to issue or transfer (lock-up) shares in the Company or similar securities by the Company and the current shareholders of the Company and indemnification of the underwriters, if any;
- (x) Appoint the underwriters or underwriters of the issue, and an agent entity, and negotiate the terms of their intervention;
- (xi) Draw up and publish such notices as may be necessary or advisable;
- (xii) Draw up, sign, execute and, where appropriate, certify any type of document relating to the issue and to the admission or incorporation of the new shares;
- (xiii) Carry out all the necessary procedures to ensure that the new shares covered by the capital increase are recorded in Iberclear's accounting records and included in BME Growth;
- (xiv) Carry out all actions that must be carried out by the Company in accordance with the terms and conditions of the capital increase;
- (xv) Agree not to execute this resolution if, in its opinion, there are reasons that justify it; and;
- (xvi) In general, to take such actions as may be necessary or advisable for the successful completion of the capital increase.

ITEM TEN ON THE AGENDA

Review and, where appropriate, approval of the following share capital increases:

Each of the proposals included under items (A) to (C) will be put to vote separately.

- (C) **Share capital increase for a maximum nominal amount of EUR 24,150,000 through the issuance and admission to circulation of up to 30,000,000 new ordinary shares with a nominal value of EUR 0.805 each (or such nominal value as may result if the Company resolves to amend it), to be fully subscribed and paid up in cash contributions, with the share premium to be determined by the board of directors, with recognition of pre-emptive subscription rights and with provision for incomplete subscription. Delegation to the board of directors, with powers of substitution, of the necessary powers to implement the capital increase and to determine the terms and conditions thereof in all matters not provided for in the resolution, pursuant to article 297.1.a) of the Spanish Companies Act (Ley de Sociedades de Capital), as well as to amend article 6 of the bylaws accordingly.**

1. Capital share increase

It is resolved to increase the share capital, by means of cash contributions, in order to increase the equity of IBI Lion SOCIMI, S.A. (the "**Company**"), by a maximum nominal amount of EUR 24,150,000, by issuing and putting into circulation a maximum of 30,000,000 new ordinary shares of EUR 0.805 of nominal value each (or EUR 0.774 of nominal value each if the increase is carried out once the capital reduction submitted to the general shareholders meeting under item Five of the agenda is effective), of the same class and series as those currently in circulation, represented by book entries.

It is also resolved to expressly delegate to the board of directors the power not to execute this resolution if, in its opinion, in view of the corporate interest, market conditions in general or the financial structure resulting from the capital increase transaction or other circumstances that may affect the Company make the execution of this resolution inadvisable or impossible.

The Company's board of directors, or the person to whom it may decide to substitute or delegate this power, shall be responsible for determining, based on market conditions at the time of execution of this resolution, taking into account the number of treasury shares and the type or issue price, the exchange ratio for the exercise of pre-emptive subscription rights.

2. Issue price

The board of directors, or the person to whom it may decide to substitute or delegate this power, shall determine, based on market conditions at the time of execution of this reduction: (i) the total nominal amount of, and the number of ordinary shares to be issued in the increase; and (ii) the unit issue price of the new shares and, in particular, the amount of the share premium, if any, to be determined for each new share:

In its decision, the board of directors shall take into account the following parameters:

- the issue price may not be less than the nominal value of the new shares, in accordance with article 59 of the consolidated text of the Spanish Companies Law as approved by Royal Legislative Decree 1/2010 of 2 July (the "**LSC**").
- (i) the total nominal amount of the capital increase shall be a maximum of EUR 24,150,000; and (ii) the maximum number of ordinary shares to be issued shall be a maximum of 30,000,000 shares

3. Maximum execution period

The board of directors, with express power of substitution in any of its members, shall be responsible for determining the date on which the resolution is to be executed within a maximum period of one year from the date of this resolution, after which time this resolutions shall be of no force and effect.

4. Addresses

The capital increase is addressed to all shareholders of the Company who acquire shares, in sufficient number, up to 23:59 hours on the same trading business day on which the corresponding announcement of the capital increase is published in the Official Gazette of the Commercial Registry (*Boletín Oficial del Registro Mercanti* or “**BORME**”), and whose transactions have been settled in the accounting records of Sociedad de Gestión de los Sistemas de Registro, Compensación y Liquidación de Valores, S.A.U. (“**Iberclear**”) and its participating entities up to the second trading business day following the publication of the announcement in the BORME, without prejudice to the possibility that other investors may subscribe shares through the acquisition of pre-emptive subscription rights, whether or not they are shareholders, as well as the possibility of offering those shares that have not been subscribed by holders of pre-emptive subscription rights to shareholders of the Company interested in subscribing an additional number of shares of the Company or to third party investors, both national and international.

In any event, the Company shall comply with any requirements necessary to be able to apply the exemption from the obligation to publish a prospectus provided for in article 1.4 of Regulation 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market and repealing Directive 2003/71/EC.

5. Subscription of the new shares

5.1. Pre-emptive subscription period

Pursuant to the provisions of article 304 of the LSC, shareholders shall be entitled to subscribe a number of shares proportional to the nominal value of the shares they hold.

Pre-emptive subscription rights shall be allocated to the Company's shareholders who have acquired shares, in sufficient number, up to 23:59 hours on the same trading business day on which the corresponding announcement of the capital increase is published in the BORME, and whose transactions have been settled in Iberclear and its participating entities up to the second trading business day following the aforementioned publication of the announcement in the BORME.

It is resolved to delegate to the board of directors, with express powers of substitution, the setting of the exchange ratio for the exercise of pre-emptive subscription rights, for which purpose it shall take into consideration the number of shares in circulation at the time of allocation of the pre-emptive subscription rights, as well as the legal regime applicable to treasury shares and the restrictions applicable to preemptive subscription rights.

Pursuant to article 503 of the LSC, in connection with the thirteenth additional provision of the same legal text, the pre-emptive subscription period shall last at least fourteen days from the publication of the announcement of the capital increase resolution in the BORME (the “**Pre-emptive Subscription Period**”).

The pre-emptive subscription rights will be transferable under the same conditions as the shares from which they derive and will be tradable on the BME Growth segment of BME MTF Equity (“**BME Growth**”), the multilateral trading system on which the Company's shares are listed for trading, pursuant to the provisions of article 306.2 of the LSC.

Pre-emptive subscription rights not exercised by the Company's shareholders to whom they have been attributed, or by those investors or shareholders who have acquired them on the market, will be automatically extinguished at the end of the Pre-emptive Subscription Period.

5.2. Additional subscription periods

The issue will be subscribed in one or more successive subscription periods and on such terms and conditions as may be determined by the board of directors. For this purpose, it is resolved to expressly delegate to the board of directors the power to establish successive subscription periods, as well as to set the conditions and terms thereof, including the duration and conditions of each of the periods.

In this respect, all shares not subscribed during the Pre-emptive Subscription Period may be distributed among shareholders of the Company interested in subscribing an additional number of shares of the Company or third party investors, both national and international, and a book-building period may be used.

In this respect, the board of directors is empowered to enter into any underwriting or placement agreement for the capital increase deemed appropriate for its successful completion, on the terms set out in section 12 of this resolution. To this end, the board of directors is empowered, with express powers of substitution, to manage this process and to participate in the appointment, if necessary, of one or more agent entities.

6. Payment of the new shares

The payment of the new shares, including their nominal value and the corresponding issue premium, to be issued under this resolution shall be made entirely by means of cash contributions at the time of subscription.

For the purposes of provisions of article 299 of the LSC, it is hereby stated that the previously issued shares of the Company are fully paid.

7. Representation of the new shares

The newly issued shares shall be represented by book entries, which shall be kept by Iberclear and its participating entities, under the terms established in the regulations in force from time to time.

8. Rights of the new shares

The new shares are ordinary shares, belong to the same class as the other ordinary shares of the Company currently in circulation and confer the same rights and obligations as the latter as from the date on which the capital increase is declared subscribed and paid up.

9. Incomplete subscription

The possibility of incomplete subscription of the capital increase is expressly provided. Accordingly, if the capital increase is not fully subscribed within the period fixed for subscription, the share capital of the Company shall be increased by the amount actually subscribed.

10. Incorporation of the new shares into the BME Growth segment of BME MTF Equity

It is resolved to request the listing of all the ordinary shares issued in execution of this resolution on BME Growth and to carry out the necessary or appropriate procedures and actions and submit the necessary documents to the competent bodies for the listing of the new shares issued as a result of the agreed capital increase, expressly stating the Company's submission to the rules that exist or may be issued in relation to BME Growth and, in particular, on trading, continued listing and delisting.

11. Amendment of article 6 of the articles of association

It is resolved to expressly authorize the board of directors, with express powers of substitution, so that, once the capital increase has been carried out, it may adapt the wording of article 6 of the articles of association relating to share capital to the final result of the capital increase.

12. Delegation of powers

It is resolved to delegate to the board of directors, pursuant to the provisions of article 297.1.a) of the LSC, with express powers of substitution, the power to set the date on which the resolution adopted to increase the share capital must be carried into effect, within the period indicated in section 3 above, and, to the extent necessary, to amend article 6 of the articles of association as appropriate with regard to the new figure for the share capital and the number of shares into which it is divided.

It is also resolved to delegate to the board of directors, also in accordance with the provisions of article 297.1.a) of the LSC and also with express powers of substitution, the power to set the terms and conditions of the capital increase in all matters not provided for in the preceding paragraphs. In particular, and without the following list being exhaustive or implying any limitation or restriction whatsoever, the powers are delegated to:

- (i) Develop, supplement and interpret this resolution, setting the terms and conditions of the capital increase in all matters not determined by the general meeting. In particular, without being exhaustive, to determine the time and manner of its implementation, the issue premium for the new shares and, therefore, to set the issue price of the new shares, the amount at which the capital increase is to be implemented, the setting of one or more additional and successive subscription periods to the Pre-emptive Subscription Period, as well as the recipients of such successive subscription periods, the possibility of offering the subscription of the increase to non-shareholders (after the end of the Pre-emptive Subscription Period) and the corresponding placement procedure or system, the date or period of subscription and payment or issue, the entities involved in the placement or in the underwriting of the issue, the method, if any, of offering the increase to non-shareholders (after the end of the Pre-emptive Subscription Period) and the corresponding placement procedure or system, the date or period of subscription and payment or issue, the entities involved in the placement or in the underwriting, where applicable, the method of allotment in the event that the securities requested by investors exceed the total securities offered, in general, the set of rules governing the issue, the exchange ratio for the exercise of pre-emptive subscription rights, the power to propose to one or more shareholders the waiver of such number of pre-emptive subscription rights held by them as may be necessary to ensure that the number of shares to be issued maintains exactly the proportion resulting from the application of the agreed exchange ratio and, in general, any other circumstances for the implementation of the increase and the issue of shares in consideration for the cash contributions;
- (ii) Declare the capital increase executed and closed once the new shares have been subscribed and paid up, determining, in the event of incomplete subscription of the increase, the final amount of the capital increase and the number of shares subscribed;
- (iii) Amend the wording of article 6 of the articles of association as a result of the outcome of the capital increase;
- (iv) Appear before the notary of their choice and convert this resolution into a public deed, as well as take such actions as may be necessary or advisable to carry out the execution, formalisation and registration of the capital increase and the corresponding amendment to the articles of association, before any public or private, Spanish or foreign entities and bodies, particularly before the Commercial Registry, including those of formalizing the resolution in a public deed, and those of clarifying, supplementing or remedying any defects or omissions that may prevent or hinder the full effectiveness of the resolution and its registration in the Commercial Registry;

- (v) Draw up, sign and file the corresponding prospectus, reduced or complete document of the capital increase and any other documentation necessary or appropriate for the authorization, verification and execution of the capital increase, as well as for the admission or listing of the new shares, with the National Securities Market Commission, BME Growth, the Governing Bodies of the Stock Exchanges, Sociedad de Bolsas, Iberclear and any other public or private, Spanish or foreign
- (vi) body or entity or registry or any other competent authority, assuming responsibility for the content of such documentation, as well as drafting, signing and submitting such additional documentation as may be required and such supplements as may be necessary or advisable, requesting verification and registration thereof by any competent authority, as the case may be, as well as drafting, signing and submitting to any other competent Spanish or foreign authorities such additional or supplementary information or documentation as may be required, assuming responsibility for the content thereof and requesting verification and registration thereof, as the case may be;
- (vii) Draft, sign and execute such public or private documents as may be necessary in connection with the international aspect, if any, of the capital increase, including the International Offering Memorandum in its preliminary and definitive versions, as well as take any actions, make any statements or dealings that may be required before the competent authorities of the United States or other countries in which shares are offered by virtue of the capital increase and, in particular, before the SEC (Securities Exchange Commission), including, if appropriate, the application for such exemptions as may be appropriate;
- (viii) Carry out any action, declaration or task before any other public or private, Spanish or foreign, body, entity or registry in order to obtain authorization, verification and subsequent execution of the capital increase;
- (ix) Negotiate, sign and execute such public or private documents as may be necessary in connection with the capital increase in accordance with practice in this type of transaction, including, in particular, one or more placement or underwriting agreements for the capital increase, if applicable, which may include, in turn and among other provisions, any representations and guarantees customary in this type of agreement, agency agreements, deposit agreements in relation to the funds raised in the capital increase or pre-agreements relating to the aforementioned placement or underwriting agreements, as well as such other agreements as may be appropriate for the best possible purpose of the capital increase, including but not limited to securities lending and green shoe option agreements in order to meet possible excess demand for the offer, agreeing the fees and other terms and conditions deemed appropriate, including commitments not to issue or transfer (lock-up) shares in the Company or similar securities by the Company and the current shareholders of the Company and indemnification of the underwriters, if any;
- (x) Appoint the underwriters or underwriters of the issue, and an agent entity, and negotiate the terms of their intervention;
- (xi) Draw up and publish such notices as may be necessary or advisable;
- (xii) Draw up, sign, execute and, where appropriate, certify any type of document relating to the issue and to the admission or incorporation of the new shares;
- (xiii) Carry out all the necessary procedures to ensure that the new shares covered by the capital increase are recorded in Iberclear's accounting records and included in BME Growth;
- (xiv) Carry out all actions that must be carried out by the Company in accordance with the terms and conditions of the capital increase;
- (xv) Agree not to execute this resolution if, in its opinion, there are reasons that justify it; and;
- (xvi) In general, to take such actions as may be necessary or advisable for the successful completion of the capital increase.

ITEM ELEVEN ON THE AGENDA

Delegation of powers for the formalisation and execution of all the resolutions passed by the general shareholders meeting, for their notarisation and for their interpretation, correction, supplementation, development and registration

Without prejudice to the delegations included in previous resolutions, it is resolved to grant joint and several powers to the board of directors, the chairman, the vice-chairman, the secretary member of the board of directors and the vice-secretary non-member of the board of directors and the rest of the members of the board of directors; so that any of them, jointly and severally, within all the scope necessary in law, may execute the resolutions adopted by this general shareholders meeting and, for this purpose, it may:

- (i) Develop, clarify, specify, interpret, execute, complement and correct them.
- (ii) Carry out any acts or legal transactions that may be necessary or appropriate to execute the resolutions, issue any public or private documents considered necessary or convenient for their full effectiveness, as well as put right any omissions, faults or errors, of content or form, that prevent their access to the Commercial Registry, the Land Registry, the Spanish Patent Office or, where appropriate, the territorial registers of associations and foundations of the regional governments that correspond to any of them, as well as, in particular, to carry out the necessary deposit of accounts in the Commercial Registry.
- (iii) Delegate jointly or severally to one or more of its members all or some of the powers considered appropriate among those that correspond to the board of directors and that have been expressly attributed to them by this general shareholders' meeting.
- (iv) Determine all the other circumstances that may be necessary, adopting and executing the resolutions necessary, publishing notices and issuing any guarantees that may be necessary for the purposes provided for by law, as well as executing the appropriate documents and fulfilling any procedures that are required, doing everything necessary by law for the full execution of what has been agreed by this general meeting.